FEMY

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Femasys (FEMY - Research Report) today and set a price target of $15.00. The company's shares closed today at $2.08.According to TipRanks, Nakae is a 4-star analyst with an average return of 7.3% and a 40.46% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Arbutus Biopharma, and Synlogic.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Femasys with a $6.50 average price target, which is a 212.76% upside from current levels. In a report released on July 29, H.C.
https://www.tipranks.com/news/blurbs/chardan-capital-remains-a-buy-on-femasys-femy?utm_source=advfn.com&utm_medium=referral